Researchers from University of Texas Report Details of New Studies and Findings in the Area of Clinical Trials and Studies (Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with ...)
By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on Clinical Research is the subject of a report. According to news reporting from Houston, Texas, by NewsRx journalists, research stated, "The primary objective of this study was to determine the safety, toxicity, and maximum tolerated dose of nanoparticle albumin-bound (nab)-paclitaxel as part of biochemotherapy for metastatic melanoma and to determine whether substituting nab-paclitaxel for less potent agents could increase response rates and duration. Treatment consisted of intravenous cisplatin (20 mg/m(2)) on days 1-4, oral temozolomide (250 mg/m(2)) on days 1-3, subcutaneous interferon-alpha (5 x 10(6) IU/m(2)) on days 1-5, and continuous intravenous interleukin-2 (9 x 10(6) IU/m(2)) for 96 h on days 1-4."
The news correspondents obtained a quote from the research from the University of Texas, "A standard 3 + 3 dose escalation method was used; the nab-paclitaxel starting dose was 100 mg/m(2) on day 1 and 70 mg/m(2) on day 5. The treatment cycle was repeated every 3 weeks and toxicity was assessed weekly. Ten patients were enrolled. Dose-limiting toxicities included diarrhea, transaminasemia, and neutropenia. The maximum tolerated dose was not identified because the nab-paclitaxel dose on day 1 at the lowest planned dose (80 mg/m(2)) caused dose-limiting toxicity in two of five patients. Of the nine patients who were evaluable for response, five had a partial response. The median time to disease progression was 5.30 months and the median overall survival was 8.73 months. Six patients developed central nervous system metastasis at a median of 5.33 months after treatment initiation. Biochemotherapy including nab-paclitaxel according to the doses and schedule regimen used in the present study has significant toxicity."
According to the news reporters, the research concluded: "Substituting dacarbazine with temozolomide did not prevent central nervous system metastasis in patients with metastatic melanoma."
For more information on this research see: Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma. Melanoma Research, 2014;24(4):342-348. Melanoma Research can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; Melanoma Research - journals.lww.com/melanomaresearch/pages/default.aspx)
Our news journalists report that additional information may be obtained by contacting A. Alrwas, Univ Texas MD Anderson Canc Center, Dept. of Biostat, Houston, TX 77030, United States. Additional authors for this research include N.E. Papadopoulos, S. Cain, S.P. Patel, K.B. Kim, T.L. Deburr, R. Bassett, W.J. Hwu, A.Y. Bedikian, M.A. Davies, S.E. Woodman and P. Hwu (see also Clinical Research).
Keywords for this news article include: Texas, Houston, Taxoids, Terpenes, Cisplatin, Cytokines, Healthcare, Paclitaxel, Hydrocarbons, Interleukins, United States, Cycloparaffins, Interferon-alpha, Clinical Research, Interferon Type I, Organic Chemicals, Biological Factors, Chlorine Compounds, Nitrogen Compounds, Platinum Compounds, Metastatic Melanoma
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC